January 25, 2021
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
November 10, 2020
October 12, 2020
Zongchao Han, MD, PhD, Barbara Savoldo, MD, PhD, and colleagues report in Nature Cancer they used a combination of CAR-Ts and interleukin (IL)-15 to treat retinoblastoma in a mouse model.
December 3, 2018
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger's Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.
